Skip to main content
Erschienen in: Journal of Neurology 3/2017

27.01.2017 | Letter to the Editors

Evidence for inflammation in Fabry’s disease? Headache and muscle involvement responding to corticosteroid and methotrexate treatment

verfasst von: Markus Kraemer, N. Karabul, P. Berlit, A. Rolfs

Erschienen in: Journal of Neurology | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Excerpt

Dear Sirs, …
Literatur
2.
Zurück zum Zitat Altarescu G, Chicco G, Whybra C, Delgado-Sanchez S, Sharon N, Beck M, Elstein D (2008) Correlation between interleukin-6 promoter and C-reactive protein (CRP) polymorphisms and CRP levels with the Mainz Severity Score Index for Fabry disease. J Inherit Metab Dis 31(1):117–123. doi:10.1007/s10545-007-0716-6 CrossRefPubMed Altarescu G, Chicco G, Whybra C, Delgado-Sanchez S, Sharon N, Beck M, Elstein D (2008) Correlation between interleukin-6 promoter and C-reactive protein (CRP) polymorphisms and CRP levels with the Mainz Severity Score Index for Fabry disease. J Inherit Metab Dis 31(1):117–123. doi:10.​1007/​s10545-007-0716-6 CrossRefPubMed
3.
Zurück zum Zitat Kikumoto Y, Kai Y, Morinaga H, Iga-Murahashi M, Matsuyama M, Sasaki T, Maruyama H, Shimotori M, Makino H, Sugiyama H, Okayama A (2010) Fabry disease exhibiting recurrent stroke and persistent inflammation. Intern Med 49(20):2247–2252CrossRefPubMed Kikumoto Y, Kai Y, Morinaga H, Iga-Murahashi M, Matsuyama M, Sasaki T, Maruyama H, Shimotori M, Makino H, Sugiyama H, Okayama A (2010) Fabry disease exhibiting recurrent stroke and persistent inflammation. Intern Med 49(20):2247–2252CrossRefPubMed
5.
Zurück zum Zitat Biancini GB, Vanzin CS, Rodrigues DB, Deon M, Ribas GS, Barschak AG, Manfredini V, Netto CB, Jardim LB, Giugliani R (1822) Vargas CR (2012) Globotriaosylceramide is correlated with oxidative stress and inflammation in Fabry patients treated with enzyme replacement therapy. Biochim Biophys Acta 2:226–232. doi:10.1016/j.bbadis.2011.11.001 Biancini GB, Vanzin CS, Rodrigues DB, Deon M, Ribas GS, Barschak AG, Manfredini V, Netto CB, Jardim LB, Giugliani R (1822) Vargas CR (2012) Globotriaosylceramide is correlated with oxidative stress and inflammation in Fabry patients treated with enzyme replacement therapy. Biochim Biophys Acta 2:226–232. doi:10.​1016/​j.​bbadis.​2011.​11.​001
6.
Zurück zum Zitat Chen KH, Chien Y, Wang KL, Leu HB, Hsiao CY, Lai YH, Wang CY, Chang YL, Lin SJ, Niu DM, Chiou SH, Yu WC (2016) Evaluation of proinflammatory prognostic biomarkers for fabry cardiomyopathy with enzyme replacement therapy. Can J Cardiol 32(10):1221, e1221–1221 e1229. doi:10.1016/j.cjca.2015.10.033 Chen KH, Chien Y, Wang KL, Leu HB, Hsiao CY, Lai YH, Wang CY, Chang YL, Lin SJ, Niu DM, Chiou SH, Yu WC (2016) Evaluation of proinflammatory prognostic biomarkers for fabry cardiomyopathy with enzyme replacement therapy. Can J Cardiol 32(10):1221, e1221–1221 e1229. doi:10.​1016/​j.​cjca.​2015.​10.​033
7.
Zurück zum Zitat Safyan R, Whybra C, Beck M, Elstein D, Altarescu G (2006) An association study of inflammatory cytokine gene polymorphisms in Fabry disease. Eur Cytokine Netw 17(4):271–275PubMed Safyan R, Whybra C, Beck M, Elstein D, Altarescu G (2006) An association study of inflammatory cytokine gene polymorphisms in Fabry disease. Eur Cytokine Netw 17(4):271–275PubMed
8.
Zurück zum Zitat Chien Y, Chien CS, Chiang HC, Huang WL, Chou SJ, Chang WC, Chang YL, Leu HB, Chen KH, Wang KL, Lai YH, Liu YY, Lu KH, Li HY, Sung YJ, Jong YJ, Chen YJ, Chen CH, Yu WC (2016) Interleukin-18 deteriorates Fabry cardiomyopathy and contributes to the development of left ventricular hypertrophy in Fabry patients with GLA IVS4+919 G>A mutation. Oncotarget. doi:10.18632/oncotarget.13552 Chien Y, Chien CS, Chiang HC, Huang WL, Chou SJ, Chang WC, Chang YL, Leu HB, Chen KH, Wang KL, Lai YH, Liu YY, Lu KH, Li HY, Sung YJ, Jong YJ, Chen YJ, Chen CH, Yu WC (2016) Interleukin-18 deteriorates Fabry cardiomyopathy and contributes to the development of left ventricular hypertrophy in Fabry patients with GLA IVS4+919 G>A mutation. Oncotarget. doi:10.​18632/​oncotarget.​13552
9.
Zurück zum Zitat Scolding NJ, Joseph F, Kirby PA, Mazanti I, Gray F, Mikol J, Ellison D, Hilton DA, Williams TL, MacKenzie JM, Xuereb JH, Love S (2005) Abeta-related angiitis: primary angiitis of the central nervous system associated with cerebral amyloid angiopathy. Brain 128(Pt 3):500–515. doi:10.1093/brain/awh379 CrossRefPubMed Scolding NJ, Joseph F, Kirby PA, Mazanti I, Gray F, Mikol J, Ellison D, Hilton DA, Williams TL, MacKenzie JM, Xuereb JH, Love S (2005) Abeta-related angiitis: primary angiitis of the central nervous system associated with cerebral amyloid angiopathy. Brain 128(Pt 3):500–515. doi:10.​1093/​brain/​awh379 CrossRefPubMed
10.
Zurück zum Zitat Sakaguchi H, Ueda A, Kosaka T, Yamashita S, Kimura E, Yamashita T, Maeda Y, Hirano T, Uchino M (2011) Cerebral amyloid angiopathy-related inflammation presenting with steroid-responsive higher brain dysfunction: case report and review of the literature. J Neuroinflammation 8:116. doi:10.1186/1742-2094-8-116 CrossRefPubMedPubMedCentral Sakaguchi H, Ueda A, Kosaka T, Yamashita S, Kimura E, Yamashita T, Maeda Y, Hirano T, Uchino M (2011) Cerebral amyloid angiopathy-related inflammation presenting with steroid-responsive higher brain dysfunction: case report and review of the literature. J Neuroinflammation 8:116. doi:10.​1186/​1742-2094-8-116 CrossRefPubMedPubMedCentral
Metadaten
Titel
Evidence for inflammation in Fabry’s disease? Headache and muscle involvement responding to corticosteroid and methotrexate treatment
verfasst von
Markus Kraemer
N. Karabul
P. Berlit
A. Rolfs
Publikationsdatum
27.01.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Neurology / Ausgabe 3/2017
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-017-8392-4

Weitere Artikel der Ausgabe 3/2017

Journal of Neurology 3/2017 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.